Health ❯ Pharmaceuticals

Drug Approval

FDA FDA Regulations Clinical Trials Novo Nordisk Regulatory Agencies Generic Drugs Sanofi Weight Loss Drugs Pain Management Market Introduction

FDA Approves Xocova as First Oral Post-Exposure COVID-19 Prophylaxis

Clinical trial data show a 67% cut in symptomatic infections when the five-day pill course is started within 72 hours of exposure.

FDA Approves Xocova as First U.S. Post-Exposure COVID-19 Antiviral

FDA Opens Early Access to KRAS-Targeting Pancreatic Cancer Pill After Strong Survival Data

Pakistan Approves Prices for 35 Essential Drugs to Ease Shortages

Corcept Investors Face Today’s Lead‑Plaintiff Deadline in Securities Case Over Relacorilant Disclosures

Multiple Indian Drugmakers Win U.S. Clearance to Sell Farxiga Generic

Corcept Investors Face April 21 Deadline to Seek Lead Role in Securities Case Over Relacorilant

SCYNEXIS Acquires Poxel’s PXL-770 for ADPKD, Plans 2026 Phase 2 Trial

Corcept Investors Pressed to Seek Lead Role in Securities Suit After FDA Rebuff of Relacorilant

FDA Grants Accelerated Approval to Avlayah for Neurologic Manifestations of Hunter Syndrome

Law Firms Urge Corcept Investors To Seek Lead Role In Securities Case Before April 21

India’s Drug Regulator Flags 90 Unapproved Fixed-Dose Medicines, Orders State Probes

Corcept Faces Securities Class Action Over Relacorilant Disclosures as Firms Rally Investors Before April 21 Deadline

FDA Approves Leucovorin for Ultra-Rare FOLR1 Folate Disorder, Declines Autism Indication

FDA Approves Vanda's Bysanti for Schizophrenia and Bipolar I in Adults

Psilocybin Therapy Clears Second Phase 3 Test as Compass Pathways Preps FDA Bid

FDA Rejects Disc Medicine’s Bitopertin for EPP After Questioning Surrogate Endpoint

ImmunityBio Sets 30-Day FDA Submission After Positive Meeting on Anktiva Expansion

FDA Delays Two Drugs in National Priority Voucher Program After Safety, Efficacy Flags

FDA Seeks Removal of Suicide Warnings From Saxenda, Wegovy and Zepbound